All News

20 February, 2019
Bicycle Therapeutics Strengthens Executive Team with Key Changes

14 February, 2019
Bicycle Therapeutics Announces Publication of its Paper Demonstrating Utility of Bicycles® as Imaging Agents

12 February, 2019
Bicycle Therapeutics Awarded £496,000 (US $640,000) SBRI Contract to Address Antimicrobial Resistance in Humans

21 November, 2018
Bicycle Therapeutics to Present at 30th Annual Piper Jaffray Healthcare Conference

14 November, 2018
Bicycle Therapeutics Named Best New Drug Developer at 2018 World ADC Awards

12 November, 2018
Bicycle Therapeutics’ Founder Sir Gregory Winter to Deliver Keynote Address at the 2018 Protein and Antibody Engineering (PEGS) Summit Europe

8 November, 2018
Bicycle Therapeutics to Present at Jefferies 2018 London Healthcare Conference

1 November, 2018
Bicycle Therapeutics Strengthens Leadership Team with Appointment of Phil Jeffrey, Ph.D., as SVP Pre-Clinical Development

17 October, 2018
Bicycle Therapeutics Announces Presentation at the Royal Society

3 October, 2018
Bicycle Therapeutics’ Founder Sir Gregory Winter Awarded Nobel Prize in Chemistry

31 May, 2018
Bicycle Therapeutics Announces Formation Of Scientific Advisory Board

31 May, 2018
Bicycle Therapeutics and Cancer Research UK Announce Presentation at 2018 American Society of Clinical Oncology Meeting

29 May, 2018
Bicycle Therapeutics to Present at Jefferies 2018 Global Healthcare Conference

25 May, 2018
Bicycle Therapeutics Announces Clinical Milestone & Expands Collaboration with Thrombogenics

24 May, 2018
Bicycle Therapeutics Expands Strategic Partnership with AstraZeneca

3 April, 2018
Bicycle Therapeutics to Present New BT1718 Data in the “New Drugs on the Horizon” Session at the 2018 American Association for Cancer Research Meeting

20 March, 2018
Bicycle Therapeutics Promotes Michael Skynner, Ph.D., to Chief Operating Officer

6 March, 2018
Bicycle Therapeutics to Present at Cowen and Company 38^th Annual Health Care Conference

13 February, 2018
Bicycle Therapeutics and Cancer Research UK announce initiation of first clinical study of a bicyclic peptide (Bicycle®)

4 January, 2018
Bicycle Therapeutics secures an Innovate UK grant to develop the next generation of antibiotics

6 December, 2017
Bicycle Therapeutics and Cancer Research UK named Best Partnership Alliance of the Year at 2017 Scrip Awards

26 October, 2017
Bicycle Therapeutics to present preclinical data on lead molecule BT1718 at the AACR-NCI-EORTC International Cancer Conference

12 October, 2017
Bicycle Therapeutics recognised with multiple biotech industry awards

26 September, 2017
Bicycle therapeutics strengthens senior management team with appointment of Maria Koehler, M.D., Ph.D., As Chief Medical Officer

6 September, 2017
Bioverativ and Bicycle Therapeutics enter into strategic research collaboration to develop therapies for Haemophilia and Sickle Cell Disease

1 August, 2017
Bicycle Therapeutics expands leadership team with appointment of Lee Kalowski as Chief Financial Officer

1 June, 2017
Bicycle Therapeutics closes £40 million ($52 million) in Series B financing to advance clinical pipeline

20 April, 2017
Bicycle Therapeutics announces a candidate preclinical milestone in its ophthalmology alliance with Thrombogenics

3 April, 2017
Bicycle Therapeutics announces presentations at the 2017 American Association for Cancer Research Annual Meeting

29 March, 2017
Bicycle Therapeutics is named winner of Business Weekly’s Disruptive Technology Award 2017

2 March, 2017
Bicycle Therapeutics to present at Cowen and Company 37th Annual Health Care Conference

5 January, 2017
Bicycle Therapeutics appoints Nicholas Keen, Ph.D., as Chief Scientific Officer

21 December, 2016
Bicycle Therapeutics is named winner of Fierce Innovation Award

15 December, 2016
Cancer Research UK and Bicycle Therapeutics collaborate to trial new therapy for advanced solid tumours

1 December, 2016
Bicycle Therapeutics announces broad partnership with AstraZeneca to develop bicyclic peptides (Bicycles®)

28 November, 2016
Bicycle Therapeutics to present preclinical data at the 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

11 October, 2016
Bicycle Therapeutics appoints Peter U. Park, Ph.D., as Vice President of Oncology Research

18 July, 2016
Bicycle Therapeutics appoints Stephen J. Hoffman, M.D., Ph.D., as Board Chairman

23 May, 2016
Bicycle Therapeutics establishes US operations and appoints Rosamond Deegan, MBA, as President and Chief Business Officer

5 May, 2016
Bicycle Therapeutics strengthens product development capabilities with key leadership appointments

21 September, 2015
Bicycle Therapeutics announces appointment of CEO

14 October, 2014
Bicycle Therapeutics announces £20M ($32M) million financing for drug development